YUPELRI revefenacin Updated Nov 9
YUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.
- YUPELRI is the first and only FDA-approved once-daily nebulized LAMA for COPD maintenance treatment, occupying a unique niche for patients who cannot use dry-powder or mist inhalers.
- YUPELRI collaboration revenue grew 15% year-over-year in Q1 2026 ($17.7M), showing steady commercial momentum.
- China NMPA approval was granted in June 2025, opening a large new market; Viatris handles ex-U.S. commercialization.
- YUPELRI faces entrenched competition from Spiriva HandiHaler (tiotropium), the market-leading LAMA; a Phase 4 head-to-head study (PIFR-2) failed to show a statistically significant difference on the primary endpoint of trough FEV1 at Day 85.
- Generic entry is possible on or after April 23, 2039 per a patent settlement with Teva, which could eventually erode U.S. market share.
- As a nebulized therapy, YUPELRI targets a narrower subset of COPD patients than dry-powder inhalers, limiting total addressable market.